Multi-Target Therapeutic Strategies for Alzheimer’s Disease: In Silico Investigation of Design of Benzyl Piperazine Derivatives as Dual-Acting Inhibitors
DOI:
https://doi.org/10.63682/jns.v14i32S.7482Keywords:
Benzyl Piperazine derivatives, Alzheimer’s disease, dual-acting inhibitors, multi-target therapeutic strategy, therapeutic compoundsAbstract
Alzheimer’s disease (AD) is advanced neurodegenerative complaint driven by pathological mechanisms, including acetyl cholinesterase over activity and beta-Amyloid plaque formation. Existing therapeutic strategies predominantly focus on single targets, offering only symptomatic relief without addressing the multifactorial countryside of the ailment. In this context, the present study aims to develop benzyl Piperazine-based results as promising multi-target-directed ligands (MTDLs) for AD management. A rational design is used to synthesize series of benzyl Piperazine derivatives, followed by extensive in silico evaluations comprising molecular docking and molecular dynamics simulation to examine their dual inhibitory possible against acetylcholinesterase (AChE) and beta-Amyloid (Aβ1–42) combination. The results revealed that several designed molecules exhibited superior binding affinities and stable interactions with both target proteins, surpassing the performance of standard inhibitors. ADMET predictions further confirmed their drug-like properties, favorable pharmacokinetic profiles, and low toxicity risks. This study is among the first to propose benzyl Piperazine-based compounds as dual-action inhibitors for AD, presenting a novel chemical scaffold with strong potential for multi-target therapeutic applications. These findings lay the groundwork for future experimental validation and open avenues in the expansion of effective disease-modifying actions for Alzheimer’s disease.
Downloads
Metrics
References
Milanifard, M., &Ramezani, M. (2025). Clinical and neurological problems and clinical tests in Alzheimer's patients specializing in Alzheimer's disease. Eurasian Journal of Chemical, Medicinal and Petroleum Research, 4(1), 244-255.
Agustini, D., Sabloak, R., Hasan, S., & Umar, T. P. (2025). The role of fusion proteins as biomarkers and therapeutic agents for Alzheimer's disease: A narrative review. NeuroMarkers, 2(2), 100041.
McGroarty, J., Salinas, S., Evans, H., Jimenez, B., Tran, V., Kadavakollu, S., ...&Atluri, V. (2025). Inflammasome-Mediated Neuroinflammation: A Key Driver in Alzheimer’s Disease Pathogenesis. Biomolecules, 15(5), 676.
Yue, Y., Jiang, W., Wang, X., Tian, Z., Cui, Y., & Zhou, X. (2025). Interactions between Oxidative Stress and Mitochondrial Dysfunction in Parkinson’s Disease: Potential of Natural Antioxidants. Journal of Biosciences and Medicines, 13(5), 75-99.
Anitha, K., Singh, M. K., Kohat, K., Chenchula, S., Padmavathi, R., Amerneni, L. S., ...& Bhatt, S. (2025). Recent insights into the neurobiology of Alzheimer’s disease and advanced treatment strategies. Molecular Neurobiology, 62(2), 2314-2332.
Kadiri, S. K., &Tiwari, P. (2025). Integrating Traditional Medicine with Network Pharmacology for Alzheimer's Treatment. Health Sciences Review, 100223.
Fatima, R., Khan, Y., Maqbool, M., Ramalingam, P. S., Khan, M. G., Bisht, A. S., &Hussain, M. S. (2025). Amyloid-β Clearance with Monoclonal Antibodies: Transforming Alzheimer’s Treatment. Current Protein & Peptide Science.
Jojo, G. M., Johnson, J., Kuppusamy, G., & Karri, V. V. S. R. (2025). Alzheimer’s Disease: Epidemiology, Etiology, Risk Factors, and Future Predictions. In Multi-Factorial Approach as a Therapeutic Strategy for the Management of Alzheimer’s Disease (pp. 41-58). Singapore: Springer Nature Singapore.
Yuan, Y., Yu, L., Bi, C., Huang, L., Su, B., Nie, J., ...& Li, Y. (2025). A new paradigm for drug discovery in the treatment of complex diseases: drug discovery and optimization. Chinese Medicine, 20(1), 40.
Turgutalp, B., & Kizil, C. (2024). Multi-target drugs for Alzheimer's disease. Trends in Pharmacological Sciences.
Niazi, S. K., Magoola, M., & Mariam, Z. (2024). Synergistic Approaches in Neurodegenerative Therapeutics: Multi-Target Drug Innovative Interventions for Alzheimer’s Disease. Pharmaceuticals, 17, 741.
Deb, D., Dhanawat, M., Bhushan, B., Pachuau, L., & Das, N. (2025). Targeting Neurodegeneration: The Emerging Role of Hybrid Drugs. Current Drug Targets, 26(6), 410-434.
Verma, A. K., Singh, K., Gupta, J. K., Kumar, S., & Jain, D. (2025). Pharmacological Approaches and Innovative Strategies for Individualized Patient Care. Recent Patents on Biotechnology.
Cummings, J. L., Teunissen, C. E., Fiske, B. K., Le Ber, I., Wildsmith, K. R., Schöll, M., ... &Scheltens, P. (2025). Biomarker-guided decision making in clinical drug development for neurodegenerative disorders. Nature Reviews Drug Discovery, 1-21.
Wang, Y., Lei, M., Zhao, Z., Wu, S., Zheng, X., Qiao, H., & Yang, X. (2025). Multi-targeted pharmacological properties of cinnamylpiperazine derivatives: a comprehensive review. Medicinal Chemistry Research, 34(1), 19-44.
Almehmadi, M., Allahyani, M., Alsaiari, A. A., Asif, M., & Kumar, S. (2025). Neuropharmacological Potential of Different Piperazine Analogs: A Recent Prospective. Mini-Reviews in Organic Chemistry, 22(1), 65-84.
Swati, Raza, A., Singh, B., &Wadhwa, P. (2025). Novel Aromatic Heterocycles for Dual MAO A and B Inhibitors: A Promising Strategy for Parkinson's Disease Treatment. ChemistrySelect, 10(1), e202404978.
Ravikumar, B., Cichońska, A., Sahni, N., Aittokallio, T., &Rahman, R. (2025). Advancements in Rational Multi‐Targeted Drug Discovery: Improving the Efficacy‐Safety Balance of Small Molecule Cancer Therapeutics. Polypharmacology: Strategies for Multi‐Target Drug Discovery, 109-125.
Liu, X., Li, Q., Yan, X., Wang, L., Qiu, J., Yao, X., & Liu, H. (2025). A Specialized and Enhanced Deep Generation Model for Active Molecular Design Targeting Kinases Guided by Affinity Prediction Models and Reinforcement Learning. Journal of Chemical Information and Modeling, 65(7), 3294-3308.
Vemulapalli, S. (2025). Targeting intrinsically disordered proteins (IDPs) in drug discovery: opportunities and challenges. Computational Methods for Rational Drug Design, 493-517.
Takomthong, P., Waiwut, P., &Boonyarat, C. (2025). Targeting multiple pathways with virtual screening to identify the multi-target agent for Alzheimer’s disease treatment. Journal of Computer-Aided Molecular Design, 39(1), 1-12.
Zhang, Z., Luo, G., Ma, Y., Wu, Z., Peng, S., Chen, S., & Wu, Y. (2025). GraphkmerDTA: integrating local sequence patterns and topological information for drug-target binding affinity prediction and applications in multi-target anti-Alzheimer’s drug discovery. Molecular Diversity, 1-18.
Huang, C., Liu, Y., Wang, S., Xia, J., Hu, D., &Xu, R. (2025). From Genes to Metabolites: HSP90B1’s Role in Alzheimer’s Disease and Potential for Therapeutic Intervention. NeuroMolecular Medicine, 27(1), 6.
Leal, C. B. Q., Zimmer, C. G., Sinatti, V. V., Soares, E. S., Poppe, B., de Wiart, A. C., ... &Bottos, R. M. (2024). Effects of the therapeutic correction of U1 snRNP complex on Alzheimer’s disease. Scientific Reports, 14(1), 1-17.
Qin, G., Song, R., Sun, J., Chen, B., Liu, Z., Han, L., ...& Li, C. (2025). Investigating the therapeutic effects of Shenzhiling oral liquid on Alzheimer’s disease: a network pharmacology and experimental approach. 3 Biotech, 15(1), 14.
Wang, F., Wang, J., Chen, T., Wang, S., Meng, X., Shen, Y., &Xu, X. (2025). Systematic Identification of Mitochondrial Signatures in Alzheimer’s Disease and Inflammatory Bowel Disease. Molecular Neurobiology, 1-31.
Tran, T. S., & Tran, T. D. (2025). Flavonoid carbamate hybrids: design, synthesis, and evaluation as multi-target enzyme inhibitors for Alzheimer's disease. RSC advances, 15(21), 16855-16868.
Wang, Y., Yan, C., Qi, Y., Zhao, R., Wan, Y., Lyu, Z., ...& Shi, J. (2025). Harnessing multi-target nanosweepers inhibiting β-amyloid aggregation, scavenging reactive oxygen species and overcoming the blood brain barrier for rescuing Alzheimer’s disease. Chemical Engineering Journal, 508, 161138.
Khoba, K., Kumar, S., &Purty, R. S. (2025). In silico analysis of Chlorophytumborivilianumphytocompounds as a multi-targeted directed ligand (MTDL) against type 2 diabetes mellitus-induced Alzheimer’s disease. Natural Product Research, 1-7.
Du, B., Zou, Q., Wang, X., Wang, H., Yang, X., Wang, Q., & Wang, K. (2025). Multi-targeted Engineered Hybrid Exosomes as Aβ Nanoscavengers and Inflammatory Modulators for Multi-pathway Intervention in Alzheimer's Disease. Biomaterials, 123403.
Wang, N.M., Shi, L., Liu, Y.B., Zhang, X.L., Yu, L.Q., Shen, S.G. and Lv, Y.K., 2025. Interaction Mechanism Between Andrographolide and α‐Glucosidase: Multispectroscopy and Molecular Docking Analyses. Luminescence, 40(6), p.e70206.
Ihsan, M., Din, F., Zamli, K.Z., Ghadi, Y.Y., Alahmadi, T.J. and Innab, N., 2025. A modified grey wolf optimizer with multi-solution crossover integration algorithm for feature selection. Journal of Ambient Intelligence and Humanized Computing, pp.1-17.
Farhangmehr, V., Imanian, H., Mohammadian, A., Cobo, J.H., Shirkhani, H. and Payeur, P., 2025. A spatiotemporal CNN-LSTM deep learning model for predicting soil temperature in diverse large-scale regional climates. Science of The Total Environment, 968, p.178901.
Yadav, L.K., Raviraju, G., Kumar, Y., Lodhi, V.K., Sarkar, S.S. and Kumar, V., 2025. Ellman’s reagent for specific turn-on chromogenic detection and differentiation of nerve agents: A platform for enzyme-free approach. Microchemical Journal, 212, p.113298.
Mari, C. and Mari, E., 2025. Stochastic DNN-based models meet hidden Markov models: A challenge on natural gas prices at the Henry Hub. Neural Computing and Applications, pp.1-20
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
